Definitive Healthcare (NASDAQ:DH) Receives “Underperform” Rating from Bank of America

Posted by Francis Steltz on Jun 29th, 2026

Definitive Healthcare (NASDAQ:DH – Get Free Report)‘s stock had its “underperform” rating restated by investment analysts at Bank of America in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $0.70 target price on the stock. Bank of America‘s price objective points to a potential upside of 6.06% from the company’s current price.

A number of other research analysts also recently commented on DH. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Barclays dropped their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a report on Monday, March 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, Definitive Healthcare currently has a consensus rating of “Reduce” and a consensus price target of $2.47.

Read Our Latest Analysis on DH

Definitive Healthcare Price Performance

DH stock opened at $0.66 on Monday. The stock’s 50 day moving average is $0.89 and its two-hundred day moving average is $1.49. Definitive Healthcare has a 52-week low of $0.62 and a 52-week high of $4.70. The company has a market capitalization of $69.64 million, a PE ratio of -0.41, a P/E/G ratio of 8.88 and a beta of 1.33. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81.

Definitive Healthcare (NASDAQ:DH – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Analysts predict that Definitive Healthcare will post 0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in shares of Definitive Healthcare in the second quarter valued at approximately $32,000. State of Alaska Department of Revenue grew its holdings in Definitive Healthcare by 109.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after buying an additional 5,970 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Definitive Healthcare in the 4th quarter valued at approximately $35,000. SG Americas Securities LLC bought a new stake in Definitive Healthcare during the 4th quarter valued at $46,000. Finally, ExodusPoint Capital Management LP acquired a new position in Definitive Healthcare during the 4th quarter worth $47,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

(Get Free Report)

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.